Skip to main content

Table 1 Characteristics of included prospective studies

From: Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies

Study (nation)

Design

Population (case/participants)

Menopausal status

Follow-up duration (years)

Exposure

Outcomes (RRs, 95% CI)

Study quality

Measurement

Range (H vs. L)a

Vatten 1993 [18] (Norway)

NCC

Subjects from serum bank; 87/235;

Pre-

5

n-3/n-6: Serum PL, GC (mg/L)

0.36 vs. 0.14

1.0 (0.4, 2.1)

Moderate

☆☆☆

☆

☆☆☆

Chajes 1999 [35] (Sweden)

NCC

Cardiovascular disease Cohort; 196/388;

Combined

2 ~ 11

LC n-3/n-6: Serum PL, GC (%tFC)

> 0.68 vs. <0.08

0.88 (0.42,1.86)

Moderate

☆☆

☆☆

☆☆☆

Saadatian-Elahi 2002 [19] (USA)

NCC

Health university Women cohort; 197/197;

Pre- and Post-

4.3

n-3/n-6: Serum PL, GC (%tFC)

4th quantile vs. reference

Pre-: 0.60 (0.24, 1.54);

High ☆☆☆☆

☆☆

☆☆☆

Post-: 0.42 (0.17, 1.08)

Wirfalt 2002 [36] (Sweden)

NCC

Malmo Diet and Cancer (MDC) Cohort; 237/673;

Post-

3 ~ 8

n-3/n-6: Diet, FFQ (g/day)

0.33 vs. 0.15

0.66 (0.41, 1.08)

Moderate

☆☆

☆☆

☆☆

Wakai 2005 [17] (Japan)

PC

Japan Collaborative Cohort Study (JACC);129/26291

Post- and Combined

7.6

n-6/n-3: Diet, FFQ (% energy)

Combined: > 4.61vs. < 3.25

Combined: 1.31 (0.78, 2.19)

High

☆☆☆

☆☆

☆☆☆

Post-: > 4.59 vs. < 3.21

Post-: 1.30 (0.66, 2.58)

Chajes 2008 [20] (Sweden)

NCC

Europe Prospective Investigation into Cancer and Nutrition (EPIC); 363/702;

Combined.

7.0

n-6/n-3: Serum PL, GC (%tFC)

5th quantile vs. reference

0.76 (0.48, 1.20)

Moderate

☆☆☆

☆☆

☆☆

Takata 2009 [37] (USA)

NCC

Beta Carotene and Retinol Efficacy Trial chort study (CARET); 103/309;

Post-.

4.4

n-3/n-6: Serum PL, GC (%tFC)

> 0.15 vs. < 0.11

0.74 (0.40, 1.36)

High

☆☆☆

☆☆

☆☆☆

Thiebaut 2009 [33] (France)

PC

EPIC Cohort; 1650/56007

Combined

8.0

n-6/n-3:Diet, FFQ, (% energy)

14.76 vs. 5.48

0.97 (0.83, 1.14)

Moderate

☆☆

☆☆

☆☆

Murff 2011 [16] (China)

PC

Shanghai Women Health Study cohort (SWHS); 712/72571;

Combined

8.0

n-6/n-3: Diet, FFQ, (g/day)

7.64 vs.5.18

1.02 (0.77, 1.34)

High

☆☆☆☆

☆☆

☆☆☆

Park 2012 [15] (USA)

PC

Multiethnic Cohort; 3885/85089;

Post-

12

n-6/n-3: Diet, FFQ, (g/1000 kcal)

> 9.60 vs. < 7.60

1.10 (0.99, 1.22)

High

☆☆☆☆

☆☆

☆☆

Sczaniecka 2012 [34] (USA)

PC

Vitamins and Lifestyle (VITAL) cohort study; 772/30252;

Post-.

6.0

n-3/n-6: Diet, FFQ, (g/day)

> 0.03 vs. < 0.005

0.84 (0.65, 1.09)

High

☆☆☆

☆☆

        

☆☆☆

  1. aH vs. L: the highest exposure quantile vs. lowest or reference.
  2. %tFC = percentage of total Fatty Acid; GC = Gas Chromatography; LC n-3 = long chain n-3 PUFAs including EPA, DPA and DHA; NCC = prospective nested case–control study; PC = prospective cohort study; n-3/n-6 = ratio of n-3/n-6 polyunsaturated fatty acids; n-6/n-3 = ratio of n-6/n-3 polyunsaturated fatty acids; FFQ = food frequency questionnaire; Serum PL = serum phospholipids.